Avanish Vellanki, Co-Founder and CEO, Rain Therapeutics talks about developing targeted therapies for patients across a range of cancers.  Their lead program tarloxotinib is currently being developed for non-small cell lung cancer patients with EGFR/Exon 20 mutations.  Avanish fills us in on what makes tarloxotinib so unique, how it has the potential to help patients who currently have no viable treatment options and the future of precision medicine in treating cancers. @Rain_Thera Rain Therapeutics